Zydus Cadila acquires US based Sentynl Therapeutics
For its foray into specialty segment in US market
Cadila Healthcare announced that Zydus Cadila has acquired Sentynl Therapeutics Inc., a US based specialty pharma company specialised in marketing of products in the pain management segment. The transaction will be EPS accretive.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content